Immunome, Inc. (IMNM)
NASDAQ:IMNM
Want to see IMNM full AI Analyst Report?
Top Page
Immunome
(NASDAQ:IMNM)
Select Model
Select Model
Rating:44Neutral
Price Target:
$18.00
▼(-26.92% Downside)
Action:Reiterated
Date:06/13/26
The score is held down primarily by weak financial performance (large ongoing losses and ~$200M+ TTM cash burn) and bearish technicals (below major moving averages with negative MACD). A low-debt balance sheet provides some support, but valuation is not meaningfully supportive given the negative P/E and no dividend.
Positive Factors
Antibody discovery platform
A platform-driven discovery model creates durable R&D throughput: it enables repeated identification of novel targets and therapeutic antibodies, supports a pipeline of candidates, and underpins recurring collaboration/licensing opportunities that can generate multi-stage revenue and partnership value over time.
Negative Factors
High operating cash burn
Sustained, large negative operating and free cash flow represent a persistent funding drain that elevates dilution and refinancing risk. Absent meaningful revenue growth or spending cuts, the magnitude of cash burn constrains strategic flexibility and makes long-term program funding dependent on external capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Antibody discovery platform
A platform-driven discovery model creates durable R&D throughput: it enables repeated identification of novel targets and therapeutic antibodies, supports a pipeline of candidates, and underpins recurring collaboration/licensing opportunities that can generate multi-stage revenue and partnership value over time.
Read all positive factors
Immunome (IMNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.08B
Dividend YieldN/A
Average Volume (3M)1.18M
Price to Earnings (P/E)―
Beta (1Y)1.68
Revenue Growth-63.29%
EPS Growth25.39%
CountryUS
Employees131
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.39
Shares Outstanding113,250,400
10 Day Avg. Volume1,476,148
30 Day Avg. Volume1,180,744
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue375.55
Enterprise Value/Gross Profit-32.32
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$35.77Price Target Upside45.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-2.14
Revenue Forecast (FY)$2.51M
Immunome Business Overview & Revenue Model
Company Description
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered...
How the Company Makes Money
Immunome primarily generates revenue through (1) collaboration and licensing arrangements with other pharmaceutical/biotechnology companies, which may include upfront payments, research funding, milestone payments tied to development/regulatory ac...
Immunome Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
70
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.01M | 6.94M | 9.04M | 14.02M | 0.00 | 0.00 |
| Gross Profit | -46.65M | 3.99M | 9.04M | 14.02M | 0.00 | 0.00 |
| EBITDA | -221.75M | -209.44M | -151.35M | -28.00M | -36.26M | -23.95M |
| Net Income | -224.59M | -212.39M | -292.96M | -106.81M | -36.90M | -24.71M |
Balance Sheet | ||||||
| Total Assets | 619.79M | 683.19M | 240.24M | 148.54M | 24.05M | 57.92M |
| Cash, Cash Equivalents and Short-Term Investments | 582.69M | 653.48M | 217.30M | 138.14M | 20.32M | 49.23M |
| Total Debt | 3.69M | 3.85M | 4.83M | 1.65M | 291.00K | 317.00K |
| Total Liabilities | 31.11M | 48.84M | 59.08M | 28.66M | 7.39M | 9.74M |
| Stockholders Equity | 588.69M | 634.34M | 181.16M | 119.88M | 16.65M | 48.19M |
Cash Flow | ||||||
| Free Cash Flow | -205.52M | -200.60M | -164.30M | -8.40M | -28.94M | -18.30M |
| Operating Cash Flow | -196.50M | -190.92M | -110.79M | -7.57M | -28.69M | -18.23M |
| Investing Cash Flow | 43.70M | 60.80M | -85.06M | -30.48M | -248.00K | -79.00K |
| Financing Cash Flow | 477.99M | 640.36M | 240.53M | 116.41M | 32.00K | 27.77M |
Immunome Technical Analysis
Negative
24.63
Price Trends
21.75
Negative
22.12
Negative
19.21
Negative
Market Momentum
-1.07
Positive
33.34
Neutral
9.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IMNM, the sentiment is Negative. The current price of 24.63 is above the 20-day moving average (MA) of 20.11, above the 50-day MA of 21.75, and above the 200-day MA of 19.21, indicating a bearish trend. The MACD of -1.07 indicates Positive momentum. The RSI at 33.34 is Neutral, neither overbought nor oversold. The STOCH value of 9.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IMNM.
Immunome Risk Analysis
Immunome disclosed 75 risk factors in its most recent earnings report. Immunome reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Immunome Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $5.04B | ― | -41.54% | ― | 39.04% | 32.40% | |
56 Neutral | $1.64B | -16.85 | -56.07% | ― | 3.42% | -11.04% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $737.75M | -11.06 | -28.90% | ― | 68.64% | 50.57% | |
44 Neutral | $1.26B | -5.11 | -45.47% | ― | -72.09% | -754.83% | |
44 Neutral | $2.08B | -9.10 | -51.15% | ― | -63.29% | 25.39% | |
43 Neutral | $745.82M | -3.26 | -161.87% | ― | ― | -6.15% |
* Healthcare Sector Average
IMNM
Immunome
18.07
8.53
89.41%
GERN
Geron
1.15
-0.40
-25.81%
IMTX
Immatics
9.43
3.33
54.59%
TNGX
Tango Therapeutics
32.90
28.11
586.85%
TSHA
Taysha Gene Therapies
5.97
3.41
133.20%
SANA
Sana Biotechnology
2.85
0.33
13.10%
Immunome Corporate Events
Executive/Board ChangesShareholder Meetings
Immunome shareholders reaffirm board, auditor and pay policies
Positive
Jun 12, 2026
Immunome, Inc. held its 2026 Annual Meeting of Stockholders on June 9, 2026, with 113,249,519 common shares eligible to vote, and shareholders elected three Class III directors — James Boylan, Sandra Swain, M.D., and Philip Wagenheim —...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.